ZLDAFZelira Therapeutics Ltd.

About Zelira Therapeutics Ltd. (ZLDAF)

Zelira Therapeutics Ltd. (ZLDAF) is a Biotechnology company headquartered in Perth, WA, Australia whose shares trade over-the-counter on the OTCQB tier.

Zelira Therapeutics Ltd is a leading global biopharmaceutical company in the research, development and commercialisation of clinically validated cannabinoid-based medicines. Zelira owns a portfolio of proprietary revenue generating products and a pipeline of candidates undergoing clinical development positioned to enter global markets. The Company is focused on developing and clinically validating branded cannabinoid-based medicines in its prescription [Rx] business for the treatment of a variety of medical conditions including insomnia, autism and chronic non-cancer pain as well as offering over the counter (OTC) products

Products and services

Zelira has established a special purpose vehicle (SPV) to conduct FDA Phase 1, Phase 2 and Phase 3 clinical trials for Zelira’s proprietary and patent protected HOPE® 1. Zelira has contributed to the SPV its HOPE® 1 product, IP and real-world data for 55% equity ownership of the SPV. Cash investors will contribute a total of circa US$35 million to fund the SPV and US FDA trials for HOPE® 1 in exchange for a cumulative equity interest of 45% of the SPV. Zelira will manage the SPV as part of its business platform. The SPV has appointed iNGENū CRO Pty Ltd (iNGENū) as its Contract Research Organisation (CRO) to lead the clinical validation and regulatory registration of the study product with the US FDA through the submission of an Investigative New Drug (IND) application. In May 2023, Zelira completed an IRB approved strategically designed multi-arm, head-to-head study targeting diabetic nerve pain. The clinical trial included a comprehensive comparison against the widely recognised and highly successful multibillion dollar revenue generating drug Lyrica® (Pregabalin). Zelira has developed Enhanced Distillate Capture and Dissolution Matrix (EDCDM) technology under the brand name Zyraydi™, that solves the problem of non-uniformity and separation of cannabinoid from powder bed, opening new ways to develop pharmaceutical grade solid oral dosage forms such as capsules and tablets. Zelira will be assessing opportunities for commercialisation of this technology.

ZLDAF key facts

Ticker symbol

ZLDAF

Market tier

OTCQB

Sector

Healthcare

Industry

Biotechnology

Headquarters

Perth, WA, Australia

Country of incorporation

AU

Year of incorporation

2003

Employees

10

Estimated market cap

$3.40M (as of Apr 16, 2025)

Shares outstanding

11,347,155

Reporting standard

International Reporting: ASX - Australian Securities Exchange

Audit status

Audited

Fiscal year end

6/30

Latest filing

Quarterly Report (Dec 31, 2024)

Zelira Therapeutics Ltd. leadership

• Oludare Odumosu — CEO
• Greg Blake — Executive Director
• Timothy Ryan Slate — Corporate Secretary

Explore more: Biotechnology stocks · Healthcare sector · OTCQB stocks · OTC stocks starting with Z